Biogen to Buy Control of MS Drug

Biogen Idec agreed to buy partner Elan's interest in Tysabri for $3.25 billion, giving it full control of the blockbuster multiple-sclerosis drug.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news